Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2018 13:08 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; August 14, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 10,726 shares as a consequence of the exercise of...
August 09, 2018 12:18 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; August 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29...
August 08, 2018 11:02 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Half of 2018

August 8, 2018; Copenhagen, Denmark; Interim Report for the First Half of 2018 Highlights USD 943 million in net sales of DARZALEX® (daratumumab), resulting in royalty income of DKK 695 millionU.S....
August 08, 2018 07:57 ET | Source: Genmab A/S

Genmab Announces Submission of U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (Daratumumab) Split Dosing Regimen

Media Release sBLA & Type II Variation submitted to U.S. FDA and the EMA respectively, seeking approval of split dosing regimen for DARZALEXApplications seek to update...
July 27, 2018 08:28 ET | Source: Genmab A/S

CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma

Company Announcement CHMP issued positive opinion for DARZALEX for front line multiple myelomaFinal decision from European Commission expected in the coming monthsOpinion based on...
July 17, 2018 06:50 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2018

Company Announcement Net sales of DARZALEX in the second quarter of 2018 totaled USD 511 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. ...
July 12, 2018 01:56 ET | Source: Genmab A/S

Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies

Company Announcement Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technologyCreation of novel...
July 03, 2018 12:45 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; July 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 24,025 shares as a consequence of the exercise of...
June 29, 2018 10:19 ET | Source: Genmab A/S

HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics

Company Announcement Genmab to pay Seattle Genetics, Inc. a milestone payment of USD 7 million under the Antibody-Drug Conjugate (ADC) program targeting AXL Milestone triggered...
June 07, 2018 14:31 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Genmab employees

Company Announcement Copenhagen, Denmark; June 7, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 5,305 restricted stock units and 14,714...